What's Happening?
A webinar titled 'In Vitro Assays for ADC Discovery: From Assay Design to Translational Insights' is set to explore the development of antibody-drug conjugates (ADCs) for treating solid tumors and hematological malignancies. The event will focus on overcoming
challenges such as limited translational insights and narrow therapeutic windows in ADC development. Attendees will learn about designing in vitro models, selecting appropriate cell lines, and applying core assays to optimize therapeutic windows. The webinar will also cover advanced analytical tools like high-content imaging and flow cytometry to generate robust data, supporting candidate selection and improving in vivo performance predictions.
Why It's Important?
Antibody-drug conjugates represent a significant advancement in cancer treatment, offering targeted therapy options for patients. However, their development is complex, requiring precise assay design and data analysis to ensure efficacy and safety. This webinar provides valuable insights into the practical aspects of ADC development, potentially accelerating the discovery and optimization of new therapeutic candidates. By addressing key challenges in ADC development, the event aims to enhance the translational success of these therapies, ultimately benefiting patients with difficult-to-treat cancers.
